Literature DB >> 7944442

[Clinical study on the effect of intra-arterial injection of mitoxantrone-lipiodol emulsion for hepatocellular carcinoma].

W Ichikawa1, S Togo, T Osanai, T Miyanaga, S Sawai, T Yamashita, Y Kawachi, Z Nihei, R Hirayama, Y Mishima.   

Abstract

To investigate the effect of intra-arterial injection of mitoxantrone emulsified with ethiodized oil, forty-eight patients with hepatocellular carcinoma were evaluated. After the treatment, ten of the patients underwent hepatectomy. In the thirty-eight unresected cases, there were 15 (39%) partial responses, which continued 1.2 to 11.8 months (mean, 5.8 months). The 1- and 2- year survival rates were 67% and 38%, respectively. The response rate was higher in cases with tumor under 5 cm in diameter. In the remaining 10 resected cases, the necrotic areas in main nodules ranged from 65% to 100% (mean, 85%). This treatment might be applied effectively to patients with small hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7944442

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  A case of advanced hepatocellular carcinoma with portal vein tumor thrombus refractory to epirubicin that showed marked decrease in tumor markers after transcatheter arterial infusion with miriplatin.

Authors:  Hiroki Nishikawa; Tadashi Inuzuka; Haruhiko Takeda; Jun Nakajima; Azusa Sakamoto; Sinichiro Henmi; Tetsurou Ishikawa; Sumio Saito; Ryuichi Kita; Toru Kimura; Yukio Osaki; Yorimitsu Koshikawa
Journal:  Case Rep Oncol       Date:  2010-06-30

2.  Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma.

Authors:  Takuji Okusaka; Shuichi Okada; Toshio Nakanishi; Shigetoshi Fujiyama; Yasuhiko Kubo
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.651

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.